Other
Anovulation
8
Pipeline Programs↗
1
Active Trials↗
7
Companies Involved↗
Anovulation is an early-stage landscape with 8 programs across 7 companies. The most active players are Ferring, Merck & Co., AbbVie. 4 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 2
No programs
Analysis
Trial Status
3
clinical trials
Active, not recruiting1 · 33%
Terminated1 · 33%
Completed1 · 33%
Clinical Trials
Trial Activity
Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation
Active, not recruiting·—·Phase 4·NCT05206448·190 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)